1. Home
  2. GXAI vs VRAX Comparison

GXAI vs VRAX Comparison

Compare GXAI & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gaxos.ai Inc.

GXAI

Gaxos.ai Inc.

N/A

Current Price

$0.53

Market Cap

8.6M

Sector

N/A

ML Signal

N/A

VRAX

Virax Biolabs Group Limited

N/A

Current Price

$2.31

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GXAI
VRAX
Founded
2021
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6M
2.1M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
GXAI
VRAX
Price
$0.53
$2.31
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 189.0K
26.3K
Earning Date
11-12-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 71.35
N/A
EPS
N/A
★ N/A
Revenue
★ $1,933,030.00
N/A
Revenue This Year
$462.16
N/A
Revenue Next Year
$30.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 47901.74
N/A
52 Week Low
$0.51
$0.10
52 Week High
$2.63
$13.19

Technical Indicators

Market Signals
Indicator
GXAI
VRAX
Relative Strength Index (RSI) 31.55 35.91
Support Level $0.51 $2.15
Resistance Level $1.30 $3.01
Average True Range (ATR) 0.04 0.18
MACD 0.00 -0.03
Stochastic Oscillator 19.66 19.05

Price Performance

Historical Comparison
GXAI
VRAX

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Share on Social Networks: